Ovid Therapeutics (OVID) EV to CFO (2017 - 2026)

Ovid Therapeutics (OVID) has reported EV to CFO for 10 consecutive years, with 21.58 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to CFO fell 792.26% year-over-year to 21.58; the trailing twelve-month figure through Jun 2026 stood at 6.93 (down 1966.74% YoY), and the FY2025 full-year result was 1.32, down 469.23% from the prior year.
• EV to CFO slipped to 21.58 in Q2 2026 per OVID's latest filing, from 10.56 in the prior quarter.
• Across five years, EV to CFO topped out at 3.12 in Q2 2025 and bottomed at 21.58 in Q2 2026.
• Historically, EV to CFO has averaged 5.18 across 5 years, with a median of 3.74 in 2022.
• The sharpest annual moves came in 2023 and 2025: EV to CFO sank 16002.77% in 2023, then surged 127.07% in 2025.
• Over 5 years, EV to CFO stood at 0.23 in 2022, then slumped by 4439.2% to 10.23 in 2023, then jumped by 87.33% to 1.3 in 2024, then slumped by 274.98% to 4.86 in 2025, then slumped by 344.23% to 21.58 in 2026.
• According to Business Quant data, EV to CFO over the past three periods registered 21.58, 10.56, and 4.86 for Q2 2026, Q1 2026, and Q4 2025 respectively.